

1 Title: Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)

2

3 Article type: Letter to the Editor

4

5 Authors:

6 Hiroshi Nishiura, M.D., Ph.D.¹

7 Tetsuro Kobayashi, M.D., M.P.H.¹

8 Takeshi Miyama, D.V.M.²

9 Ayako Suzuki, M.D., M.P.H.¹

10 Sung-mok Jung, M.P.H.¹

11 Katsuma Hayashi, M.D.¹

12 Ryo Kinoshita, M.H.Sc.¹

13 Yichi Yang, B.Sc.¹

14 Baoyin Yuan, M.Sc.¹

15 Andrei R. Akhmetzhanov, Ph.D.¹

16 Natalie M. Linton, M.P.H.¹

17 1. Graduate School of Medicine, Hokkaido University, Sapporo, 060-8638, Japan

18 2. Osaka Institute of Public Health, Osaka, 537-0025, Japan

19 (Correspondence to Hiroshi Nishiura at: Address: Kita 15 Jo Nishi 7 Chome, Kita-ku,

20 Sapporo-shi, Hokkaido 060-8638, Japan, Tel: +81-11-706-5066; Fax: +81-11-706-7819;

21 Email: nishiurah@med.hokudai.ac.jp)

22

23 The number of novel coronavirus (COVID-19) cases worldwide continues to grow, and

24 the gap between reports from China and statistical estimates of incidence based on cases

25 diagnosed outside China indicates that a substantial number of cases are underdiagnosed
26 (Nishiura et al., 2020a). Estimation of the asymptomatic ratio—the percentage of carriers
27 with no symptoms—will improve understanding of COVID-19 transmission and the
28 spectrum of disease it causes, providing insight into epidemic spread. Although the
29 asymptomatic ratio is conventionally estimated using seroepidemiological data (Carrat et
30 al., 2008; Hsieh et al., 2014), collection of these data requires significant logistical effort,
31 time, and cost. Instead, we propose to estimate the asymptomatic ratio by using
32 information on Japanese nationals that evacuated from Wuhan, China on chartered
33 flights.

34 Figure 1 illustrates the flow of the evacuation process. By 6 February 2020 a
35 total of $N=565$ citizens were evacuated. Among them, $pN=63$ (11.2%) were considered
36 symptomatic upon arrival based on (1) temperature screening before disembarkation,
37 and (2) face-to-face interviews eliciting information on symptoms including fever,
38 cough, and other non-specific symptoms consistent with COVID-19. All passengers
39 additionally undertook reverse transcription polymerase chain reaction (RT-PCR)
40 testing, and $m=5$ asymptomatic and $n=7$ symptomatic passengers tested positive for
41 2019-nCoV.

42 Employing a Bayes theorem, the asymptomatic ratio is defined as

$$\text{Pr}(\text{asymptomatic} | \text{infection}) = \frac{\text{Pr}(\text{infection} | \text{asymptomatic}) \text{Pr}(\text{asymptomatic})}{\text{Pr}(\text{infection})},$$

43 which can be calculated as $m/(n+m)$, as seen in Figure 1. The asymptomatic ratio is thus
44 estimated at 41.6% (95% confidence interval (CI): 16.7%, 66.7%) among evacuees.
45 Because fourteen days have elapsed since their departure from Wuhan—longer than the
46 95th percentile estimate of the COVID-19 incubation period (Li et al., 2020; Linton et

47 al., 2020)—there is very little probability that the five virus-positive asymptomatic
48 individuals will develop symptoms. Should one of the five becomes symptomatic in the
49 future, the overall asymptomatic ratio would decrease to 33.3% (95% CI: 8.3%, 58.3%).

50 In general, asymptomatic infections cannot be recognized if they are not
51 confirmed by RT-PCR or other laboratory testing, and symptomatic cases may not be
52 detected if they do not seek medical attention (Nishiura et al., 2020b). Estimates such as
53 this therefore provide important insight by using a targeted population to assess
54 prevalence of asymptomatic viral shedding (Kupferschmidt & Cohen, 2020). Despite a
55 small sample size, our estimation indicates that perhaps nearly a half of
56 COVID-19-infected individuals are asymptomatic. This ratio is slightly smaller than
57 that of influenza, which was estimated at 56–80% (Hsieh et al., 2014) using similar
58 definitions for symptomatic individuals. There is great need for further studies on the
59 prevalence of asymptomatic COVID-19 infections to guide epidemic control efforts.

60

61 **Acknowledgments**

62 H.N. received funding support from Japan Agency for Medical Research and
63 Development [grant number: JP18fk0108050] the Japan Society for the Promotion of
64 Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI in Japanese
65 abbreviation) grant nos. 17H04701, 17H05808, 18H04895 and 19H01074, and the
66 Japan Science and Technology Agency (JST) Core Research for Evolutional Science
67 and Technology (CREST) program [grant number: JPMJCR1413]. NML received a

68 graduate study scholarship from the Ministry of Education, Culture, Sports, Science and
69 Technology, Japan. The funders had no role in study design, data collection and analysis,
70 decision to publish, or preparation of the manuscript.

71 **Conflict of interest:**

72 We declare that we have no conflict of interest.

73

74 **References:**

- 75 1. Nishiura H, Jung SM, Linton NM, Kinoshita R, Yang Y, Hayashi K, Kobayashi T,
76 Yuan B, Akhmetzhanov AR. The Extent of Transmission of Novel Coronavirus in
77 Wuhan, China, 2020a. *J Clin Med.* 2020;9(2). pii: E330. doi: 10.3390/jcm9020330.
- 78 2. Carrat F, Vergu E, Ferguson NM, Lemaître M, Cauchemez S, Leach S, Valleron AJ:
79 Time lines of infection and disease in human influenza: a review of volunteer challenge
80 studies. *Am J Epidemiol.* 2008 ; 167 (7): 775-785. doi: 10.1093/aje/kwm375.
- 81 3. Hsieh Y, Tsai C, Lin C, et al. Asymptomatic ratio for seasonal H1N1 influenza
82 infection among schoolchildren in Taiwan. *BMC Infect Dis* 2014;14: 80. doi:
83 10.1186/1471-2334-14-80.
- 84 4. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong
85 JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Li M, Tu W, Chen C,
86 Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z,
87 Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JTK, Gao GF, Cowling
88 BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of
89 Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020; in press. doi:
90 10.1056/NEJMoa2001316

- 91 5. Linton NM, Kobayashi T, Yang Y, Hayashi K, Andrei, AR, Jung S-M, Yuan B,
92 Kinoshita R, Nishiura H. Epidemiological characteristics of novel coronavirus infection:
93 A statistical analysis of publicly available case data. medRxiv. 2020; doi:
94 10.1101/2020.01.26.20018754.
- 95 6. Nishiura H, Kobayashi T, Yang Y, Hayashi K, Miyama T, Kinoshita R, Linton NM,
96 Jung SM, Yuan B, Suzuki A, Akhmetzhanov AR. The Rate of Underascertainment of
97 Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data
98 on Evacuation Flights. J Clin Med. 2020b;9(2). pii: E419. doi: 10.3390/jcm9020419.
- 99 7. Kupferschmidt K, Cohen J. ‘This beast is moving very fast.’ Will the new coronavirus
100 be contained—or go pandemic? Science 2020; 5 February 2020.
101 doi:10.1126/science.abb1701

102

103 Figure legend

104 Figure 1. Flow of symptom screening and viral testing for passengers on chartered
105 evacuation flights from Wuhan, China to Japan

106 The flow of Japanese residents evacuating from Wuhan and screened in Japan. A total of
107 N passengers were evaluated of which a fraction p were symptomatic upon arrival.
108 Among symptomatic and asymptomatic individuals, n and m persons tested positive for
109 the virus via reverse transcription polymerase chain reaction (RT-PCR).

Entry screening

RT-PCR

Charter flights



N passengers

